URMC-099-C

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameURMC-099-C
Drug Alias Namemixed lineage kinase 3 inhibitors (Califia/University of Nebraska/University of Rochester)Mixed Lineage Kinase 3 Inhibitor (Califia/University of Nebraska/University of Rochester)MLK-3 inhibitors (Califia/University of Rochester/University of Nebraska)URMC-099-CURMC-099
ClassificationSmall molecules
Mechanisms of ActionMitogen-activated protein kinase kinase kinase 11 inhibitorsTumor necrosis factor α inhibitorsNeuroprotectants
TargetsMitogen-activated protein kinase kinase kinase 11Tumor necrosis factor α
Therapy Area/IndicationsMultiple SclerosisMetabolic Dysfunction-Associated Steatotic Liver DiseaseAIDS Dementia Complex +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity of Rochester Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCalifia Bio IncUniversity of Rochester Medical CenterUniversity Of Nebraska Medical Center
Active IndicationsN/A
Inactive IndicationsMultiple SclerosisMetabolic Dysfunction-Associated Steatotic Liver DiseaseAIDS Dementia Complex +[5] 

Other Information

ATC CodeN/A
Related LinksN/A